AI Article Synopsis

  • Lambert Eaton Myasthenic Syndrome (LEMS) is a rare neuromuscular disorder characterized by muscle weakness, lack of reflexes, and autonomic problems.
  • * The diagnosis involves clinical evaluations and tests for specific antibodies against voltage-gated calcium channels, along with neurophysiological assessments.
  • * A case study is presented of a 69-year-old man with prostate cancer and a long history of smoking, who experienced lower limb weakness and difficulty with stairs.

Article Abstract

Lambert Eaton myasthenic syndrome (LEMS) is a rare disorder of the neuromuscular junction. The representative clinical triad consists of proximal muscular weakness, areflexia and autonomic dysfunction. The diagnosis is based on the clinical findings confirmed by voltage-gated calcium channels antibody titer and neurophysiology. We present a 69 year old male with prostate adenocarcinoma and 30 years history of smoking, referred for muscle weakness in the lower limbs and difficulty to climb the stairs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10852129PMC
http://dx.doi.org/10.15386/mpr-2541DOI Listing

Publication Analysis

Top Keywords

lambert eaton
8
eaton myasthenic
8
myasthenic syndrome
8
prostate adenocarcinoma
8
acute onset
4
onset lambert
4
syndrome prostate
4
adenocarcinoma case
4
case report
4
report lambert
4

Similar Publications

Nutritional epidemiology aims to link dietary exposures to chronic disease, but the instruments for evaluating dietary intake are inaccurate. One way to identify unreliable data and the sources of errors is to compare estimated intakes with the total energy expenditure (TEE). In this study, we used the International Atomic Energy Agency Doubly Labeled Water Database to derive a predictive equation for TEE using 6,497 measures of TEE in individuals aged 4 to 96 years.

View Article and Find Full Text PDF

Late onset cerebellar ataxia syndrome after non-paraneoplastic Lambert-Eaton myasthenic syndrome: a case study.

BMC Neurol

January 2025

Neuromuscular Neurology, Advocate Health, 1850 Dempster Street, Park Ridge, IL, 60068, USA.

This is an unusual case of voltage gated calcium channel (VGCC) antibodies leading to two distinct and chronologically separated neurologic syndromes without the presence of an underlying neoplasm. Lambert Eaton Myasthenic Syndrome (LEMS) presented five years prior to cerebellar ataxia. Both LEMS and cerebellar ataxia were responsive to treatment, but not the same therapy.

View Article and Find Full Text PDF

Background: Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disorder of the presynaptic neuromuscular junction associated with antibody mediated dysfunction of voltage-gated calcium channels (VGCCs). LEMS can exist as a paraneoplastic syndrome, paraneoplastic-LEMS (P-LEMS), when associated with tumors, most commonly, small cell lung carcinoma (SCLC) or as a non-paraneoplastic condition (NP-LEMS) when no malignancies are detected.

Methods: A retrospective chart review was conducted in 3 tertiary hospitals in Saudi Arabia for patients diagnosed with LEMS between January 2010 and January 2020.

View Article and Find Full Text PDF

Background: Paraneoplastic Neurological Syndromes (PNS) constitute a heterogeneous cluster of disease manifestations related to various cancers. Small Cell Lung Cancer (SCLC) is strongly related to PNS. This narrative review conducted a survey in the available PubMed literature to highlight the appearance of PNSs in SCLC cases and discuss published research highlights on the subject so that general practitioners can be acquainted with the medical phenomenon present in SCLC patients.

View Article and Find Full Text PDF

What Is in the Neuromuscular Junction Literature?

J Clin Neuromuscul Dis

December 2024

Departments of Neurology and Pathology (Neuropathology), University of Pittsburgh School of Medicine, Pittsburgh, PA.

This update starts with an interesting series of children and adults with congenital myasthenic syndrome with a DOK7 variant. The next section is on autoimmune myasthenia gravis (MG) epidemiology, cost of care, and hospitalizations. A number of studies on the newer treatments are discussed including a phase 2 trial of nipocalimab and recommendations for using some of these drugs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!